Report content
Flag "Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib"
Help us keep the community safe by telling us why this story should be reviewed.
Article
By hyperstorm0b